Paper16815744
Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T and 4 others. Sleep Med, 2006. Cited by 89 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Papers, record 16815744. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16815744
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypnotics and Sedatives | Major topic |
| Pyridines | Major topic |
| Sleep Initiation and Maintenance Disorders | Major topic |
| Adolescent | |
| Adult | |
| Delayed-Action Preparations | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Polysomnography | |
| Psychomotor Performance | |
| Sleep | |
| Surveys and Questionnaires | |
| Zolpidem |
Source PubMed
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,957,444 | Insomnia disorder. | Nat Rev Dis Primers | 2026 | https://conductscience.org/library/papers/41957444 | PubMed |
| 41,005,810 | Impact of positive airway pressure for chronic hypercapnic respiratory failure on sleep quality: a systematic review and meta-analysis. | Eur Respir Rev | 2025 | https://conductscience.org/library/papers/41005810 | PubMed |
| 40,225,286 | Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression-Insomnia Questionnaire. | Nat Sci Sleep | 2025 | https://conductscience.org/library/papers/40225286 | PubMed |
| 38,748,321 | Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder. | Neurol Ther | 2024 | https://conductscience.org/library/papers/38748321 | PubMed |
| 38,370,879 | 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association. | Sleep Sci | 2023 | https://conductscience.org/library/papers/38370879 | PubMed |
| 37,829,761 | Severe chronic abuse of zolpidem for over 10 years: a case report and review of similar cases. | Front Psychiatry | 2023 | https://conductscience.org/library/papers/37829761 | PubMed |
| 37,513,909 | Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513909 | PubMed |
| 36,947,394 | The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials. | Drugs | 2023 | https://conductscience.org/library/papers/36947394 | PubMed |
| 36,061,292 | Case report: Chronological symptom profile after cessation of overdose zolpidem in a patient with comorbid bipolar disorder-from anxiety, craving, paresthesia and influenza-like symptoms to seizures and hallucinations. | Front Psychiatry | 2022 | https://conductscience.org/library/papers/36061292 | PubMed |
| 35,749,758 | Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. | J Clin Psychopharmacol | 2022 | https://conductscience.org/library/papers/35749758 | PubMed |
| 35,402,894 | Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder. | Sleep Med X | 2022 | https://conductscience.org/library/papers/35402894 | PubMed |
| 35,162,009 | External Auditory Stimulation as a Non-Pharmacological Sleep Aid. | Sensors (Basel) | 2022 | https://conductscience.org/library/papers/35162009 | PubMed |
| 34,708,126 | An Update on Assessment, Therapeutic Management, and Patents on Insomnia. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/34708126 | PubMed |
| 34,121,443 | Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis. | J Manag Care Spec Pharm | 2021 | https://conductscience.org/library/papers/34121443 | PubMed |
| 31,496,087 | The assessment and management of insomnia: an update. | World Psychiatry | 2019 | https://conductscience.org/library/papers/31496087 | PubMed |
| 30,144,651 | How representative are insomnia clinical trials? | Sleep Med | 2018 | https://conductscience.org/library/papers/30144651 | PubMed |
| 29,792,241 | Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trial. | Psychol Med | 2019 | https://conductscience.org/library/papers/29792241 | PubMed |
| 27,998,379 | Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. | J Clin Sleep Med | 2017 | https://conductscience.org/library/papers/27998379 | PubMed |
| 27,397,664 | Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. | J Clin Sleep Med | 2016 | https://conductscience.org/library/papers/27397664 | PubMed |
| 26,609,210 | Pharmacological Treatment of Insomnia. | P T | 2015 | https://conductscience.org/library/papers/26609210 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16815744
GET https://conductscience.org/api/papers/v1/16815744/cited_by?page=2